Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery.
作者信息
Kushnir Margarita, Gali Radhika, Alexander Mariam, Billett Henny H
机构信息
Division of Hematology, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY.
出版信息
Blood Adv. 2023 Jan 24;7(2):224-226. doi: 10.1182/bloodadvances.2021006696.
Abstract
摘要
相似文献
1
Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery.直接口服Xa因子抑制剂用于治疗减重手术后的静脉血栓栓塞症。
Blood Adv. 2023 Jan 24;7(2):224-226. doi: 10.1182/bloodadvances.2021006696.
2
Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.静脉血栓栓塞症抗凝延长治疗患者换用直接口服抗凝剂后对患者满意度的影响：SWAN 研究。
PLoS One. 2020 Jun 4;15(6):e0234048. doi: 10.1371/journal.pone.0234048. eCollection 2020.
3
Recurrent Thrombi in an Obese Patient With History of Bariatric Surgery Despite Anti-Xa Therapy.肥胖患者在接受抗 Xa 治疗的情况下仍反复出现血栓，该患者有减重手术史。
J Pharm Pract. 2022 Oct;35(5):811-816. doi: 10.1177/08971900211004837. Epub 2021 Apr 8.
4
Bariatric venous thromboembolism prophylaxis: an update on the literature.减重相关静脉血栓栓塞症预防：文献更新。
Expert Rev Hematol. 2019 Sep;12(9):763-771. doi: 10.1080/17474086.2019.1634542. Epub 2019 Aug 5.
5
Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.低分子量肝素与华法林及口服Xa因子抑制剂预防肿瘤患者复发性静脉血栓栓塞的回顾性比较：Re-CLOT研究
J Oncol Pharm Pract. 2018 Oct;24(7):494-500. doi: 10.1177/1078155217718382. Epub 2017 Jul 16.
6
Oral Anticoagulant Use in Morbid Obesity and Post Bariatric Surgery: A Review.病态肥胖及减重手术后口服抗凝剂的应用：综述
Am J Med. 2021 Dec;134(12):1465-1475. doi: 10.1016/j.amjmed.2021.07.017. Epub 2021 Aug 15.
7
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.与华法林相比，直接口服Xa因子抑制剂在病态肥胖患者中的疗效和安全性：一项单中心图表数据回顾性分析
Lancet Haematol. 2019 Jul;6(7):e359-e365. doi: 10.1016/S2352-3026(19)30086-9. Epub 2019 May 24.
8
Prophylactic measures to reduce the risk of venous thromboembolism in bariatric surgery patients.降低肥胖症手术患者静脉血栓栓塞风险的预防措施。
Surg Obes Relat Dis. 2007 Sep-Oct;3(5):494-5. doi: 10.1016/j.soard.2007.06.005.
9
Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.学术医学中心妇科恶性肿瘤患者使用利伐沙班的评估：一项试点研究。
J Oncol Pharm Pract. 2019 Mar;25(2):362-368. doi: 10.1177/1078155217739683. Epub 2017 Nov 20.
10
Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-Center Registry.利伐沙班在静脉血栓栓塞合并活动性恶性肿瘤患者中的疗效和安全性：一项单中心注册研究
Am J Med. 2016 Jun;129(6):615-9. doi: 10.1016/j.amjmed.2015.12.025. Epub 2016 Jan 18.
本文引用的文献
1
Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series.接受减重手术后服用阿哌沙班或利伐沙班的患者的不良事件：一项回顾性病例系列研究。
J Thromb Thrombolysis. 2022 Apr;53(3):601-606. doi: 10.1007/s11239-021-02573-6. Epub 2021 Sep 24.
2
Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.肥胖患者使用直接口服抗凝剂治疗和预防静脉血栓栓塞症：ISTH SSC 抗凝控制小组委员会的最新沟通。
J Thromb Haemost. 2021 Aug;19(8):1874-1882. doi: 10.1111/jth.15358. Epub 2021 Jul 14.
3
Safety and Efficacy of Oral Anticoagulants for Atrial Fibrillation in Patients After Bariatric Surgery.肥胖症手术患者心房颤动口服抗凝剂的安全性和疗效。
Am J Cardiol. 2020 Dec 1;136:76-80. doi: 10.1016/j.amjcard.2020.09.020. Epub 2020 Sep 15.
4
American Society for Metabolic and Bariatric Surgery 2018 estimate of metabolic and bariatric procedures performed in the United States.美国代谢与减重外科学会 2018 年美国代谢与减重手术实施预估。
Surg Obes Relat Dis. 2020 Apr;16(4):457-463. doi: 10.1016/j.soard.2019.12.022. Epub 2020 Jan 3.
5
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.与华法林相比，直接口服Xa因子抑制剂在病态肥胖患者中的疗效和安全性：一项单中心图表数据回顾性分析
Lancet Haematol. 2019 Jul;6(7):e359-e365. doi: 10.1016/S2352-3026(19)30086-9. Epub 2019 May 24.
6
The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study.减重手术对直接口服抗凝药利伐沙班的影响：扩展研究。
Surg Obes Relat Dis. 2018 Dec;14(12):1890-1896. doi: 10.1016/j.soard.2018.08.025. Epub 2018 Sep 19.
7
Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects.健康受试者中阿哌沙班的区域性胃肠道吸收。
J Clin Pharmacol. 2018 Jul;58(7):965-971. doi: 10.1002/jcph.1097. Epub 2018 Mar 26.
8
Adjustments to warfarin dosing after gastric bypass and sleeve gastrectomy.胃旁路和袖状胃切除术后华法林剂量的调整。
Surg Obes Relat Dis. 2018 May;14(5):700-706. doi: 10.1016/j.soard.2017.12.021. Epub 2018 Jan 2.
9
The effect of bariatric surgery on direct-acting oral anticoagulant drug levels.减重手术对直接口服抗凝药物水平的影响。
Thromb Res. 2018 Mar;163:190-195. doi: 10.1016/j.thromres.2017.11.006. Epub 2017 Nov 15.
10
Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance.减重手术后口服抗凝剂的使用：文献综述与临床指南
Am J Med. 2017 May;130(5):517-524. doi: 10.1016/j.amjmed.2016.12.033. Epub 2017 Feb 1.
Zotero 插件